|
Actavis (formerly known as Watson Pharmaceuticals and Actavis, plc, prior to the acquisition of Allergan, inc) is a global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis has a commercial presence across approximately 100 countries. The company has global headquarters in Dublin, Ireland and administrative headquarters in Parsippany-Troy Hills, New Jersey, United States.〔(【引用サイトリンク】title=Actavis plc )〕 Actavis, plc markets a portfolio of brand products through six franchises in key therapeutic categories including: Aesthetics/Dermatology/Plastic Surgery; Neurosciences/CNS; Eye Care; Women’s Health and Urology; GI and Cystic Fibrosis; and Cardiovascular Disease and Infectious Disease.〔(【引用サイトリンク】work=Actavis plc )〕 The company's product portfolio includes Botox,〔(【引用サイトリンク】work=Allergan )〕 Namenda, Restasis,〔(【引用サイトリンク】work=Allergan )〕 Linzess, Bystolic,〔(【引用サイトリンク】work=Actavis )〕 Juvederm,〔(【引用サイトリンク】work=Allergan )〕 Latisse,〔(【引用サイトリンク】work=Allergan )〕 Lo Loestrin Fe, Estrace, Teflaro, Dalvance, Ozurdex,〔(【引用サイトリンク】work=Allergan )〕 Optive,〔(【引用サイトリンク】work=Allergan )〕 Natrelle,〔(【引用サイトリンク】work=Allergan )〕 Viibryd, Liletta, Saphris,〔(【引用サイトリンク】work=Actavis plc )〕 Enablex, Actonel, Androderm, Gelnique and others. Actavis, plc also operates the world's third-largest generics business. The company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.〔(【引用サイトリンク】work=First Word Pharma )〕 Actavis, plc is also developing biosimilars products in oncology and other therapeutic categories, and currently has a portfolio of five biosimilar products in development.〔(【引用サイトリンク】title=Can Actavis deliver a promised $6B boost from this pipeline )〕 Actavis, plc has more than 40 manufacturing and distribution facilities around the world, with a capacity of approximately 40 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.〔(【引用サイトリンク】title=Actavis Confirms Favorable Ruling In Generic Pulmicort Respules Patent Suit )〕 On June 15, 2015, Actavis, plc changed its name to Allergan, plc, but the company's U.S. and Canadian generics business will continue to operate under the Actavis name. In July 2015, Allergan, Plc announced it would sell its Generics division of the company to Teva Pharmaceuticals for $40.5 billion.〔http://www.allergan.com/NEWS/News/Thomson-Reuters/Allergan-Accelerates-Transformation-to-Branded-Gro〕 ==History== The company was founded in the spring of 1983,〔(【引用サイトリンク】title=ACT Profile - Actavis plc Ordinary Shares Stock - Yahoo! Finance )〕 when, with funding from friends and family, colleagues Allen Chao, Ph.D. and David Hsia, Ph.D., began a small drug development enterprise. Just two months later, the founders established an initial product development and analytical laboratory with six employees (including both founders) in a leased space in Libertyville, Illinois. By late fall of the same year, the company moved to Southern California into an initial 2,000-square-foot (190 m2) leased facility in Corona, and the development and manufacturing of generic pharmaceuticals began.〔(【引用サイトリンク】work=TBI )〕 The Corona site became the corporate headquarters for the rapidly expanding U.S. company. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Actavis」の詳細全文を読む スポンサード リンク
|